Cormedix affirms FY2026 sales guidance at $325M–$345M
Cormedix (NASDAQ: CRMD) affirms FY2026 sales guidance of $325.000M–$345.000M, compared with a $334.089M estimate, with the range unchanged from the prior outlook.
Cormedix (NASDAQ: CRMD ) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $334.089 million estimate.